nodes	percent_of_prediction	percent_of_DWPC	metapath
Methoxsalen—CYP2A6—Prednisolone—multiple sclerosis	0.161	0.246	CbGbCtD
Methoxsalen—CYP2A6—Dexamethasone—multiple sclerosis	0.0949	0.145	CbGbCtD
Methoxsalen—CYP1A1—Dexamethasone—multiple sclerosis	0.0811	0.124	CbGbCtD
Methoxsalen—CYP3A4—Fingolimod—multiple sclerosis	0.0778	0.119	CbGbCtD
Methoxsalen—CYP3A4—Methylprednisolone—multiple sclerosis	0.0502	0.0767	CbGbCtD
Methoxsalen—CYP3A4—Triamcinolone—multiple sclerosis	0.038	0.0582	CbGbCtD
Methoxsalen—CYP3A4—Mitoxantrone—multiple sclerosis	0.0366	0.056	CbGbCtD
Methoxsalen—CYP3A4—Betamethasone—multiple sclerosis	0.0326	0.0499	CbGbCtD
Methoxsalen—CYP3A4—Prednisolone—multiple sclerosis	0.0322	0.0492	CbGbCtD
Methoxsalen—CYP3A4—Prednisone—multiple sclerosis	0.0304	0.0465	CbGbCtD
Methoxsalen—CYP3A4—Dexamethasone—multiple sclerosis	0.019	0.029	CbGbCtD
Methoxsalen—CYP2A13—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00429	0.0603	CbGpPWpGaD
Methoxsalen—CYP2A13—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00429	0.0603	CbGpPWpGaD
Methoxsalen—CYP2A13—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00424	0.0595	CbGpPWpGaD
Methoxsalen—CYP2A13—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00424	0.0595	CbGpPWpGaD
Methoxsalen—CYP2A13—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00348	0.0489	CbGpPWpGaD
Methoxsalen—CYP2A13—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00348	0.0489	CbGpPWpGaD
Methoxsalen—Sunburn—Methotrexate—multiple sclerosis	0.00306	0.0111	CcSEcCtD
Methoxsalen—Leukoderma—Dexamethasone—multiple sclerosis	0.00299	0.0109	CcSEcCtD
Methoxsalen—Leukoderma—Betamethasone—multiple sclerosis	0.00299	0.0109	CcSEcCtD
Methoxsalen—Inflammation—Cladribine—multiple sclerosis	0.00291	0.0106	CcSEcCtD
Methoxsalen—Depression—Fingolimod—multiple sclerosis	0.00278	0.0101	CcSEcCtD
Methoxsalen—Leukoderma—Prednisone—multiple sclerosis	0.0026	0.00946	CcSEcCtD
Methoxsalen—Systemic lupus erythematosus—Triamcinolone—multiple sclerosis	0.00253	0.00919	CcSEcCtD
Methoxsalen—Skin hyperpigmentation—Triamcinolone—multiple sclerosis	0.00236	0.00856	CcSEcCtD
Methoxsalen—Skin hyperpigmentation—Methylprednisolone—multiple sclerosis	0.00235	0.00854	CcSEcCtD
Methoxsalen—Folliculitis—Triamcinolone—multiple sclerosis	0.00223	0.0081	CcSEcCtD
Methoxsalen—Folliculitis—Methylprednisolone—multiple sclerosis	0.00222	0.00808	CcSEcCtD
Methoxsalen—Leukoderma—Methotrexate—multiple sclerosis	0.00218	0.00791	CcSEcCtD
Methoxsalen—Skin hyperpigmentation—Dexamethasone—multiple sclerosis	0.00214	0.00776	CcSEcCtD
Methoxsalen—Skin hyperpigmentation—Betamethasone—multiple sclerosis	0.00214	0.00776	CcSEcCtD
Methoxsalen—Blister—Prednisolone—multiple sclerosis	0.00211	0.00768	CcSEcCtD
Methoxsalen—Folliculitis—Dexamethasone—multiple sclerosis	0.00202	0.00735	CcSEcCtD
Methoxsalen—Folliculitis—Betamethasone—multiple sclerosis	0.00202	0.00735	CcSEcCtD
Methoxsalen—Blister—Triamcinolone—multiple sclerosis	0.00194	0.00706	CcSEcCtD
Methoxsalen—CYP2A13—Biological oxidations—CYP27B1—multiple sclerosis	0.00185	0.026	CbGpPWpGaD
Methoxsalen—CYP2A13—Biological oxidations—CYP24A1—multiple sclerosis	0.00185	0.026	CbGpPWpGaD
Methoxsalen—CYP2A13—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00182	0.0256	CbGpPWpGaD
Methoxsalen—CYP2A13—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00182	0.0256	CbGpPWpGaD
Methoxsalen—Infection—Fingolimod—multiple sclerosis	0.00177	0.00642	CcSEcCtD
Methoxsalen—Blister—Dexamethasone—multiple sclerosis	0.00176	0.00641	CcSEcCtD
Methoxsalen—Blister—Betamethasone—multiple sclerosis	0.00176	0.00641	CcSEcCtD
Methoxsalen—Skin disorder—Fingolimod—multiple sclerosis	0.00173	0.00627	CcSEcCtD
Methoxsalen—Hypotension—Fingolimod—multiple sclerosis	0.00166	0.00603	CcSEcCtD
Methoxsalen—Herpes simplex—Prednisolone—multiple sclerosis	0.00165	0.006	CcSEcCtD
Methoxsalen—Skin hyperpigmentation—Methotrexate—multiple sclerosis	0.00156	0.00565	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00154	0.00558	CcSEcCtD
Methoxsalen—Folliculitis—Methotrexate—multiple sclerosis	0.00147	0.00535	CcSEcCtD
Methoxsalen—Inflammation—Methylprednisolone—multiple sclerosis	0.00144	0.00523	CcSEcCtD
Methoxsalen—CYP2A6—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.00141	0.0198	CbGpPWpGaD
Methoxsalen—Herpes simplex—Dexamethasone—multiple sclerosis	0.00138	0.00501	CcSEcCtD
Methoxsalen—Herpes simplex—Betamethasone—multiple sclerosis	0.00138	0.00501	CcSEcCtD
Methoxsalen—Skin exfoliation—Triamcinolone—multiple sclerosis	0.00134	0.00486	CcSEcCtD
Methoxsalen—Skin exfoliation—Methylprednisolone—multiple sclerosis	0.00133	0.00485	CcSEcCtD
Methoxsalen—Arrhythmia—Cladribine—multiple sclerosis	0.00127	0.0046	CcSEcCtD
Methoxsalen—Pruritus—Fingolimod—multiple sclerosis	0.00126	0.00457	CcSEcCtD
Methoxsalen—Erythema—Cladribine—multiple sclerosis	0.00124	0.00449	CcSEcCtD
Methoxsalen—Skin exfoliation—Betamethasone—multiple sclerosis	0.00121	0.00441	CcSEcCtD
Methoxsalen—Skin exfoliation—Dexamethasone—multiple sclerosis	0.00121	0.00441	CcSEcCtD
Methoxsalen—Dizziness—Fingolimod—multiple sclerosis	0.00118	0.00427	CcSEcCtD
Methoxsalen—Dermatitis bullous—Prednisolone—multiple sclerosis	0.00116	0.0042	CcSEcCtD
Methoxsalen—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00115	0.0162	CbGpPWpGaD
Methoxsalen—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00115	0.0162	CbGpPWpGaD
Methoxsalen—Ill-defined disorder—Cladribine—multiple sclerosis	0.00115	0.00416	CcSEcCtD
Methoxsalen—CYP2A6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00114	0.016	CbGpPWpGaD
Methoxsalen—CYP2A6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00114	0.016	CbGpPWpGaD
Methoxsalen—Headache—Fingolimod—multiple sclerosis	0.00111	0.00405	CcSEcCtD
Methoxsalen—Malaise—Cladribine—multiple sclerosis	0.00111	0.00405	CcSEcCtD
Methoxsalen—Dermatitis bullous—Triamcinolone—multiple sclerosis	0.00106	0.00387	CcSEcCtD
Methoxsalen—Skin exfoliation—Prednisone—multiple sclerosis	0.00106	0.00384	CcSEcCtD
Methoxsalen—Discomfort—Cladribine—multiple sclerosis	0.00104	0.00377	CcSEcCtD
Methoxsalen—Arrhythmia—Azathioprine—multiple sclerosis	0.00103	0.00374	CcSEcCtD
Methoxsalen—Dry skin—Prednisolone—multiple sclerosis	0.00101	0.00368	CcSEcCtD
Methoxsalen—Oedema—Cladribine—multiple sclerosis	0.00101	0.00366	CcSEcCtD
Methoxsalen—Herpes simplex—Methotrexate—multiple sclerosis	0.001	0.00365	CcSEcCtD
Methoxsalen—Infection—Cladribine—multiple sclerosis	0.001	0.00364	CcSEcCtD
Methoxsalen—Skin disorder—Cladribine—multiple sclerosis	0.000979	0.00356	CcSEcCtD
Methoxsalen—CYP2A13—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000966	0.0136	CbGpPWpGaD
Methoxsalen—Dermatitis bullous—Dexamethasone—multiple sclerosis	0.000966	0.00351	CcSEcCtD
Methoxsalen—Dermatitis bullous—Betamethasone—multiple sclerosis	0.000966	0.00351	CcSEcCtD
Methoxsalen—Inflammation—Methotrexate—multiple sclerosis	0.000954	0.00346	CcSEcCtD
Methoxsalen—Hypotension—Cladribine—multiple sclerosis	0.000942	0.00342	CcSEcCtD
Methoxsalen—CYP2A6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000933	0.0131	CbGpPWpGaD
Methoxsalen—CYP2A6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000933	0.0131	CbGpPWpGaD
Methoxsalen—Ill-defined disorder—Azathioprine—multiple sclerosis	0.000932	0.00338	CcSEcCtD
Methoxsalen—Insomnia—Cladribine—multiple sclerosis	0.000912	0.00331	CcSEcCtD
Methoxsalen—Malaise—Azathioprine—multiple sclerosis	0.000906	0.00329	CcSEcCtD
Methoxsalen—Skin exfoliation—Methotrexate—multiple sclerosis	0.000883	0.00321	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00087	0.00316	CcSEcCtD
Methoxsalen—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000862	0.0121	CbGpPWpGaD
Methoxsalen—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000862	0.0121	CbGpPWpGaD
Methoxsalen—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000858	0.0121	CbGpPWpGaD
Methoxsalen—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000858	0.0121	CbGpPWpGaD
Methoxsalen—CYP1A1—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000847	0.0119	CbGpPWpGaD
Methoxsalen—CYP1A1—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000847	0.0119	CbGpPWpGaD
Methoxsalen—Dry skin—Dexamethasone—multiple sclerosis	0.000846	0.00307	CcSEcCtD
Methoxsalen—Dry skin—Betamethasone—multiple sclerosis	0.000846	0.00307	CcSEcCtD
Methoxsalen—Discomfort—Azathioprine—multiple sclerosis	0.000845	0.00307	CcSEcCtD
Methoxsalen—Arrhythmia—Mitoxantrone—multiple sclerosis	0.000833	0.00303	CcSEcCtD
Methoxsalen—Feeling abnormal—Cladribine—multiple sclerosis	0.000831	0.00302	CcSEcCtD
Methoxsalen—Infection—Azathioprine—multiple sclerosis	0.000814	0.00296	CcSEcCtD
Methoxsalen—Erythema—Mitoxantrone—multiple sclerosis	0.000812	0.00295	CcSEcCtD
Methoxsalen—Urticaria—Cladribine—multiple sclerosis	0.000801	0.00291	CcSEcCtD
Methoxsalen—Body temperature increased—Cladribine—multiple sclerosis	0.000797	0.00289	CcSEcCtD
Methoxsalen—Skin disorder—Azathioprine—multiple sclerosis	0.000796	0.00289	CcSEcCtD
Methoxsalen—Dysgeusia—Mitoxantrone—multiple sclerosis	0.000795	0.00289	CcSEcCtD
Methoxsalen—CYP2A13—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000783	0.011	CbGpPWpGaD
Methoxsalen—Hypotension—Azathioprine—multiple sclerosis	0.000766	0.00278	CcSEcCtD
Methoxsalen—Ill-defined disorder—Mitoxantrone—multiple sclerosis	0.000753	0.00274	CcSEcCtD
Methoxsalen—Hypersensitivity—Cladribine—multiple sclerosis	0.000743	0.0027	CcSEcCtD
Methoxsalen—Dry skin—Prednisone—multiple sclerosis	0.000737	0.00268	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000736	0.0103	CbGpPWpGaD
Methoxsalen—Malaise—Mitoxantrone—multiple sclerosis	0.000732	0.00266	CcSEcCtD
Methoxsalen—Pruritus—Cladribine—multiple sclerosis	0.000713	0.00259	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000708	0.00257	CcSEcCtD
Methoxsalen—CYP1A1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000696	0.00977	CbGpPWpGaD
Methoxsalen—CYP1A1—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000696	0.00977	CbGpPWpGaD
Methoxsalen—Arrhythmia—Prednisolone—multiple sclerosis	0.000683	0.00248	CcSEcCtD
Methoxsalen—Discomfort—Mitoxantrone—multiple sclerosis	0.000683	0.00248	CcSEcCtD
Methoxsalen—Feeling abnormal—Azathioprine—multiple sclerosis	0.000675	0.00245	CcSEcCtD
Methoxsalen—Dizziness—Cladribine—multiple sclerosis	0.000667	0.00242	CcSEcCtD
Methoxsalen—Erythema—Prednisolone—multiple sclerosis	0.000666	0.00242	CcSEcCtD
Methoxsalen—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000665	0.00935	CbGpPWpGaD
Methoxsalen—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000665	0.00935	CbGpPWpGaD
Methoxsalen—Oedema—Mitoxantrone—multiple sclerosis	0.000663	0.00241	CcSEcCtD
Methoxsalen—Infection—Mitoxantrone—multiple sclerosis	0.000658	0.00239	CcSEcCtD
Methoxsalen—Body temperature increased—Azathioprine—multiple sclerosis	0.000648	0.00235	CcSEcCtD
Methoxsalen—Skin disorder—Mitoxantrone—multiple sclerosis	0.000644	0.00234	CcSEcCtD
Methoxsalen—Rash—Cladribine—multiple sclerosis	0.000636	0.00231	CcSEcCtD
Methoxsalen—Dermatitis—Cladribine—multiple sclerosis	0.000635	0.00231	CcSEcCtD
Methoxsalen—Headache—Cladribine—multiple sclerosis	0.000631	0.00229	CcSEcCtD
Methoxsalen—Arrhythmia—Triamcinolone—multiple sclerosis	0.000629	0.00228	CcSEcCtD
Methoxsalen—Arrhythmia—Methylprednisolone—multiple sclerosis	0.000627	0.00228	CcSEcCtD
Methoxsalen—Hypotension—Mitoxantrone—multiple sclerosis	0.000619	0.00225	CcSEcCtD
Methoxsalen—Ill-defined disorder—Prednisolone—multiple sclerosis	0.000618	0.00224	CcSEcCtD
Methoxsalen—Depression—Prednisone—multiple sclerosis	0.000618	0.00224	CcSEcCtD
Methoxsalen—Erythema—Triamcinolone—multiple sclerosis	0.000612	0.00222	CcSEcCtD
Methoxsalen—Erythema—Methylprednisolone—multiple sclerosis	0.000611	0.00222	CcSEcCtD
Methoxsalen—Hypersensitivity—Azathioprine—multiple sclerosis	0.000604	0.00219	CcSEcCtD
Methoxsalen—Malaise—Prednisolone—multiple sclerosis	0.000601	0.00218	CcSEcCtD
Methoxsalen—Dysgeusia—Triamcinolone—multiple sclerosis	0.0006	0.00218	CcSEcCtD
Methoxsalen—Nausea—Cladribine—multiple sclerosis	0.000599	0.00217	CcSEcCtD
Methoxsalen—Vertigo—Prednisolone—multiple sclerosis	0.000598	0.00217	CcSEcCtD
Methoxsalen—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000589	0.00827	CbGpPWpGaD
Methoxsalen—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000583	0.00212	CcSEcCtD
Methoxsalen—Arrhythmia—Betamethasone—multiple sclerosis	0.00057	0.00207	CcSEcCtD
Methoxsalen—Arrhythmia—Dexamethasone—multiple sclerosis	0.00057	0.00207	CcSEcCtD
Methoxsalen—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.000568	0.00206	CcSEcCtD
Methoxsalen—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.000567	0.00206	CcSEcCtD
Methoxsalen—Discomfort—Prednisolone—multiple sclerosis	0.00056	0.00203	CcSEcCtD
Methoxsalen—Erythema—Betamethasone—multiple sclerosis	0.000556	0.00202	CcSEcCtD
Methoxsalen—Erythema—Dexamethasone—multiple sclerosis	0.000556	0.00202	CcSEcCtD
Methoxsalen—Malaise—Triamcinolone—multiple sclerosis	0.000552	0.00201	CcSEcCtD
Methoxsalen—Malaise—Methylprednisolone—multiple sclerosis	0.000551	0.002	CcSEcCtD
Methoxsalen—Vertigo—Triamcinolone—multiple sclerosis	0.00055	0.002	CcSEcCtD
Methoxsalen—Vertigo—Methylprednisolone—multiple sclerosis	0.000549	0.00199	CcSEcCtD
Methoxsalen—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000547	0.00769	CbGpPWpGaD
Methoxsalen—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000547	0.00769	CbGpPWpGaD
Methoxsalen—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000546	0.00198	CcSEcCtD
Methoxsalen—Oedema—Prednisolone—multiple sclerosis	0.000544	0.00197	CcSEcCtD
Methoxsalen—Dizziness—Azathioprine—multiple sclerosis	0.000542	0.00197	CcSEcCtD
Methoxsalen—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00054	0.00759	CbGpPWpGaD
Methoxsalen—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00054	0.00759	CbGpPWpGaD
Methoxsalen—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.00053	0.00192	CcSEcCtD
Methoxsalen—Urticaria—Mitoxantrone—multiple sclerosis	0.000526	0.00191	CcSEcCtD
Methoxsalen—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000524	0.0019	CcSEcCtD
Methoxsalen—Rash—Azathioprine—multiple sclerosis	0.000517	0.00188	CcSEcCtD
Methoxsalen—Dermatitis—Azathioprine—multiple sclerosis	0.000516	0.00188	CcSEcCtD
Methoxsalen—Depression—Methotrexate—multiple sclerosis	0.000516	0.00187	CcSEcCtD
Methoxsalen—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000516	0.00187	CcSEcCtD
Methoxsalen—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000516	0.00187	CcSEcCtD
Methoxsalen—Discomfort—Triamcinolone—multiple sclerosis	0.000515	0.00187	CcSEcCtD
Methoxsalen—Discomfort—Methylprednisolone—multiple sclerosis	0.000514	0.00187	CcSEcCtD
Methoxsalen—Headache—Azathioprine—multiple sclerosis	0.000513	0.00186	CcSEcCtD
Methoxsalen—Malaise—Betamethasone—multiple sclerosis	0.000501	0.00182	CcSEcCtD
Methoxsalen—Malaise—Dexamethasone—multiple sclerosis	0.000501	0.00182	CcSEcCtD
Methoxsalen—Oedema—Triamcinolone—multiple sclerosis	0.0005	0.00182	CcSEcCtD
Methoxsalen—Vertigo—Betamethasone—multiple sclerosis	0.000499	0.00181	CcSEcCtD
Methoxsalen—Vertigo—Dexamethasone—multiple sclerosis	0.000499	0.00181	CcSEcCtD
Methoxsalen—Arrhythmia—Prednisone—multiple sclerosis	0.000497	0.0018	CcSEcCtD
Methoxsalen—Infection—Triamcinolone—multiple sclerosis	0.000497	0.0018	CcSEcCtD
Methoxsalen—CYP2A6—Biological oxidations—CYP24A1—multiple sclerosis	0.000496	0.00697	CbGpPWpGaD
Methoxsalen—CYP2A6—Biological oxidations—CYP27B1—multiple sclerosis	0.000496	0.00697	CbGpPWpGaD
Methoxsalen—Infection—Methylprednisolone—multiple sclerosis	0.000495	0.0018	CcSEcCtD
Methoxsalen—Insomnia—Prednisolone—multiple sclerosis	0.000492	0.00179	CcSEcCtD
Methoxsalen—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000488	0.00177	CcSEcCtD
Methoxsalen—Nausea—Azathioprine—multiple sclerosis	0.000487	0.00177	CcSEcCtD
Methoxsalen—Skin disorder—Methylprednisolone—multiple sclerosis	0.000484	0.00176	CcSEcCtD
Methoxsalen—Erythema—Prednisone—multiple sclerosis	0.000484	0.00176	CcSEcCtD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000469	0.00659	CbGpPWpGaD
Methoxsalen—Discomfort—Betamethasone—multiple sclerosis	0.000467	0.0017	CcSEcCtD
Methoxsalen—Discomfort—Dexamethasone—multiple sclerosis	0.000467	0.0017	CcSEcCtD
Methoxsalen—Hypotension—Methylprednisolone—multiple sclerosis	0.000466	0.00169	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000462	0.00649	CbGpPWpGaD
Methoxsalen—Oedema—Betamethasone—multiple sclerosis	0.000454	0.00165	CcSEcCtD
Methoxsalen—Oedema—Dexamethasone—multiple sclerosis	0.000454	0.00165	CcSEcCtD
Methoxsalen—Insomnia—Triamcinolone—multiple sclerosis	0.000452	0.00164	CcSEcCtD
Methoxsalen—Insomnia—Methylprednisolone—multiple sclerosis	0.000451	0.00164	CcSEcCtD
Methoxsalen—Infection—Betamethasone—multiple sclerosis	0.000451	0.00164	CcSEcCtD
Methoxsalen—Infection—Dexamethasone—multiple sclerosis	0.000451	0.00164	CcSEcCtD
Methoxsalen—Ill-defined disorder—Prednisone—multiple sclerosis	0.000449	0.00163	CcSEcCtD
Methoxsalen—CYP2A13—Metabolism—SRM—multiple sclerosis	0.000449	0.00631	CbGpPWpGaD
Methoxsalen—Feeling abnormal—Prednisolone—multiple sclerosis	0.000448	0.00163	CcSEcCtD
Methoxsalen—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000443	0.00623	CbGpPWpGaD
Methoxsalen—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000443	0.00623	CbGpPWpGaD
Methoxsalen—Dyspepsia—Triamcinolone—multiple sclerosis	0.00044	0.0016	CcSEcCtD
Methoxsalen—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000439	0.00159	CcSEcCtD
Methoxsalen—Malaise—Prednisone—multiple sclerosis	0.000436	0.00159	CcSEcCtD
Methoxsalen—Vertigo—Prednisone—multiple sclerosis	0.000435	0.00158	CcSEcCtD
Methoxsalen—Urticaria—Prednisolone—multiple sclerosis	0.000432	0.00157	CcSEcCtD
Methoxsalen—Hypotension—Betamethasone—multiple sclerosis	0.000424	0.00154	CcSEcCtD
Methoxsalen—Hypotension—Dexamethasone—multiple sclerosis	0.000424	0.00154	CcSEcCtD
Methoxsalen—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000422	0.00593	CbGpPWpGaD
Methoxsalen—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000422	0.00593	CbGpPWpGaD
Methoxsalen—Rash—Mitoxantrone—multiple sclerosis	0.000418	0.00152	CcSEcCtD
Methoxsalen—Dermatitis—Mitoxantrone—multiple sclerosis	0.000417	0.00152	CcSEcCtD
Methoxsalen—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000417	0.00586	CbGpPWpGaD
Methoxsalen—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000417	0.00586	CbGpPWpGaD
Methoxsalen—CYP2A13—Biological oxidations—POMC—multiple sclerosis	0.000416	0.00584	CbGpPWpGaD
Methoxsalen—Headache—Mitoxantrone—multiple sclerosis	0.000415	0.00151	CcSEcCtD
Methoxsalen—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000412	0.0015	CcSEcCtD
Methoxsalen—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000411	0.00149	CcSEcCtD
Methoxsalen—Insomnia—Dexamethasone—multiple sclerosis	0.00041	0.00149	CcSEcCtD
Methoxsalen—Insomnia—Betamethasone—multiple sclerosis	0.00041	0.00149	CcSEcCtD
Methoxsalen—CYP1A1—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000408	0.00574	CbGpPWpGaD
Methoxsalen—Discomfort—Prednisone—multiple sclerosis	0.000407	0.00148	CcSEcCtD
Methoxsalen—Erythema—Methotrexate—multiple sclerosis	0.000404	0.00147	CcSEcCtD
Methoxsalen—CYP1A1—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000402	0.00565	CbGpPWpGaD
Methoxsalen—Hypersensitivity—Prednisolone—multiple sclerosis	0.0004	0.00145	CcSEcCtD
Methoxsalen—Dyspepsia—Betamethasone—multiple sclerosis	0.000399	0.00145	CcSEcCtD
Methoxsalen—Dyspepsia—Dexamethasone—multiple sclerosis	0.000399	0.00145	CcSEcCtD
Methoxsalen—Urticaria—Triamcinolone—multiple sclerosis	0.000397	0.00144	CcSEcCtD
Methoxsalen—Urticaria—Methylprednisolone—multiple sclerosis	0.000396	0.00144	CcSEcCtD
Methoxsalen—Dysgeusia—Methotrexate—multiple sclerosis	0.000396	0.00144	CcSEcCtD
Methoxsalen—Body temperature increased—Triamcinolone—multiple sclerosis	0.000395	0.00144	CcSEcCtD
Methoxsalen—Oedema—Prednisone—multiple sclerosis	0.000395	0.00143	CcSEcCtD
Methoxsalen—Nausea—Mitoxantrone—multiple sclerosis	0.000394	0.00143	CcSEcCtD
Methoxsalen—Infection—Prednisone—multiple sclerosis	0.000392	0.00143	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000392	0.00142	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000392	0.00142	CcSEcCtD
Methoxsalen—Skin disorder—Prednisone—multiple sclerosis	0.000384	0.00139	CcSEcCtD
Methoxsalen—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000379	0.00532	CbGpPWpGaD
Methoxsalen—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000375	0.00136	CcSEcCtD
Methoxsalen—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000374	0.00136	CcSEcCtD
Methoxsalen—Feeling abnormal—Betamethasone—multiple sclerosis	0.000374	0.00136	CcSEcCtD
Methoxsalen—CYP1A1—Biological oxidations—CYP24A1—multiple sclerosis	0.000369	0.00519	CbGpPWpGaD
Methoxsalen—CYP1A1—Biological oxidations—CYP27B1—multiple sclerosis	0.000369	0.00519	CbGpPWpGaD
Methoxsalen—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000368	0.00134	CcSEcCtD
Methoxsalen—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000367	0.00133	CcSEcCtD
Methoxsalen—Malaise—Methotrexate—multiple sclerosis	0.000365	0.00132	CcSEcCtD
Methoxsalen—CYP1A1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000364	0.00512	CbGpPWpGaD
Methoxsalen—CYP1A1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000364	0.00512	CbGpPWpGaD
Methoxsalen—Vertigo—Methotrexate—multiple sclerosis	0.000363	0.00132	CcSEcCtD
Methoxsalen—Urticaria—Dexamethasone—multiple sclerosis	0.00036	0.00131	CcSEcCtD
Methoxsalen—Urticaria—Betamethasone—multiple sclerosis	0.00036	0.00131	CcSEcCtD
Methoxsalen—Dizziness—Prednisolone—multiple sclerosis	0.000359	0.00131	CcSEcCtD
Methoxsalen—Body temperature increased—Dexamethasone—multiple sclerosis	0.000359	0.0013	CcSEcCtD
Methoxsalen—Body temperature increased—Betamethasone—multiple sclerosis	0.000359	0.0013	CcSEcCtD
Methoxsalen—Insomnia—Prednisone—multiple sclerosis	0.000357	0.0013	CcSEcCtD
Methoxsalen—Pruritus—Triamcinolone—multiple sclerosis	0.000354	0.00128	CcSEcCtD
Methoxsalen—Pruritus—Methylprednisolone—multiple sclerosis	0.000353	0.00128	CcSEcCtD
Methoxsalen—Dyspepsia—Prednisone—multiple sclerosis	0.000348	0.00126	CcSEcCtD
Methoxsalen—Rash—Prednisolone—multiple sclerosis	0.000343	0.00124	CcSEcCtD
Methoxsalen—Dermatitis—Prednisolone—multiple sclerosis	0.000342	0.00124	CcSEcCtD
Methoxsalen—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000342	0.00481	CbGpPWpGaD
Methoxsalen—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000342	0.00481	CbGpPWpGaD
Methoxsalen—Headache—Prednisolone—multiple sclerosis	0.000341	0.00124	CcSEcCtD
Methoxsalen—Discomfort—Methotrexate—multiple sclerosis	0.00034	0.00124	CcSEcCtD
Methoxsalen—Dizziness—Triamcinolone—multiple sclerosis	0.000331	0.0012	CcSEcCtD
Methoxsalen—Dizziness—Methylprednisolone—multiple sclerosis	0.00033	0.0012	CcSEcCtD
Methoxsalen—Infection—Methotrexate—multiple sclerosis	0.000328	0.00119	CcSEcCtD
Methoxsalen—Feeling abnormal—Prednisone—multiple sclerosis	0.000325	0.00118	CcSEcCtD
Methoxsalen—Nausea—Prednisolone—multiple sclerosis	0.000323	0.00117	CcSEcCtD
Methoxsalen—Pruritus—Dexamethasone—multiple sclerosis	0.000321	0.00117	CcSEcCtD
Methoxsalen—Pruritus—Betamethasone—multiple sclerosis	0.000321	0.00117	CcSEcCtD
Methoxsalen—Skin disorder—Methotrexate—multiple sclerosis	0.000321	0.00116	CcSEcCtD
Methoxsalen—CYP2A13—Metabolism—CYP27B1—multiple sclerosis	0.000316	0.00444	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—CYP24A1—multiple sclerosis	0.000316	0.00444	CbGpPWpGaD
Methoxsalen—Rash—Triamcinolone—multiple sclerosis	0.000315	0.00114	CcSEcCtD
Methoxsalen—Dermatitis—Triamcinolone—multiple sclerosis	0.000315	0.00114	CcSEcCtD
Methoxsalen—Rash—Methylprednisolone—multiple sclerosis	0.000314	0.00114	CcSEcCtD
Methoxsalen—Dermatitis—Methylprednisolone—multiple sclerosis	0.000314	0.00114	CcSEcCtD
Methoxsalen—Urticaria—Prednisone—multiple sclerosis	0.000314	0.00114	CcSEcCtD
Methoxsalen—Headache—Triamcinolone—multiple sclerosis	0.000313	0.00114	CcSEcCtD
Methoxsalen—Headache—Methylprednisolone—multiple sclerosis	0.000312	0.00113	CcSEcCtD
Methoxsalen—Body temperature increased—Prednisone—multiple sclerosis	0.000312	0.00113	CcSEcCtD
Methoxsalen—Hypotension—Methotrexate—multiple sclerosis	0.000308	0.00112	CcSEcCtD
Methoxsalen—Dizziness—Dexamethasone—multiple sclerosis	0.0003	0.00109	CcSEcCtD
Methoxsalen—Dizziness—Betamethasone—multiple sclerosis	0.0003	0.00109	CcSEcCtD
Methoxsalen—Insomnia—Methotrexate—multiple sclerosis	0.000299	0.00108	CcSEcCtD
Methoxsalen—Nausea—Triamcinolone—multiple sclerosis	0.000297	0.00108	CcSEcCtD
Methoxsalen—Nausea—Methylprednisolone—multiple sclerosis	0.000296	0.00108	CcSEcCtD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000295	0.00414	CbGpPWpGaD
Methoxsalen—Hypersensitivity—Prednisone—multiple sclerosis	0.000291	0.00106	CcSEcCtD
Methoxsalen—Dyspepsia—Methotrexate—multiple sclerosis	0.000291	0.00106	CcSEcCtD
Methoxsalen—CYP2A13—Metabolism—GPC5—multiple sclerosis	0.000289	0.00406	CbGpPWpGaD
Methoxsalen—Rash—Dexamethasone—multiple sclerosis	0.000286	0.00104	CcSEcCtD
Methoxsalen—Rash—Betamethasone—multiple sclerosis	0.000286	0.00104	CcSEcCtD
Methoxsalen—Dermatitis—Betamethasone—multiple sclerosis	0.000286	0.00104	CcSEcCtD
Methoxsalen—Dermatitis—Dexamethasone—multiple sclerosis	0.000286	0.00104	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000285	0.00104	CcSEcCtD
Methoxsalen—Headache—Betamethasone—multiple sclerosis	0.000284	0.00103	CcSEcCtD
Methoxsalen—Headache—Dexamethasone—multiple sclerosis	0.000284	0.00103	CcSEcCtD
Methoxsalen—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000282	0.00396	CbGpPWpGaD
Methoxsalen—Pruritus—Prednisone—multiple sclerosis	0.000279	0.00102	CcSEcCtD
Methoxsalen—Feeling abnormal—Methotrexate—multiple sclerosis	0.000272	0.000988	CcSEcCtD
Methoxsalen—Nausea—Betamethasone—multiple sclerosis	0.000269	0.000979	CcSEcCtD
Methoxsalen—Nausea—Dexamethasone—multiple sclerosis	0.000269	0.000979	CcSEcCtD
Methoxsalen—Urticaria—Methotrexate—multiple sclerosis	0.000262	0.000952	CcSEcCtD
Methoxsalen—Dizziness—Prednisone—multiple sclerosis	0.000261	0.000949	CcSEcCtD
Methoxsalen—Body temperature increased—Methotrexate—multiple sclerosis	0.000261	0.000948	CcSEcCtD
Methoxsalen—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.00026	0.00366	CbGpPWpGaD
Methoxsalen—CYP2A6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000259	0.00364	CbGpPWpGaD
Methoxsalen—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000256	0.0036	CbGpPWpGaD
Methoxsalen—Rash—Prednisone—multiple sclerosis	0.000249	0.000905	CcSEcCtD
Methoxsalen—Dermatitis—Prednisone—multiple sclerosis	0.000249	0.000904	CcSEcCtD
Methoxsalen—Headache—Prednisone—multiple sclerosis	0.000247	0.000899	CcSEcCtD
Methoxsalen—Hypersensitivity—Methotrexate—multiple sclerosis	0.000243	0.000883	CcSEcCtD
Methoxsalen—CYP2A13—Metabolism—RRM1—multiple sclerosis	0.00024	0.00337	CbGpPWpGaD
Methoxsalen—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.000236	0.00331	CbGpPWpGaD
Methoxsalen—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.000236	0.00331	CbGpPWpGaD
Methoxsalen—Nausea—Prednisone—multiple sclerosis	0.000235	0.000852	CcSEcCtD
Methoxsalen—Pruritus—Methotrexate—multiple sclerosis	0.000234	0.000848	CcSEcCtD
Methoxsalen—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000232	0.00327	CbGpPWpGaD
Methoxsalen—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000232	0.00327	CbGpPWpGaD
Methoxsalen—Dizziness—Methotrexate—multiple sclerosis	0.000218	0.000793	CcSEcCtD
Methoxsalen—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000218	0.00306	CbGpPWpGaD
Methoxsalen—CYP2A6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.00021	0.00295	CbGpPWpGaD
Methoxsalen—Rash—Methotrexate—multiple sclerosis	0.000208	0.000756	CcSEcCtD
Methoxsalen—Dermatitis—Methotrexate—multiple sclerosis	0.000208	0.000755	CcSEcCtD
Methoxsalen—Headache—Methotrexate—multiple sclerosis	0.000207	0.000751	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000199	0.00279	CbGpPWpGaD
Methoxsalen—Nausea—Methotrexate—multiple sclerosis	0.000196	0.000712	CcSEcCtD
Methoxsalen—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000193	0.00271	CbGpPWpGaD
Methoxsalen—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000182	0.00256	CbGpPWpGaD
Methoxsalen—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000182	0.00256	CbGpPWpGaD
Methoxsalen—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000179	0.00252	CbGpPWpGaD
Methoxsalen—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000179	0.00252	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000177	0.00249	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000176	0.00248	CbGpPWpGaD
Methoxsalen—CYP1A1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000156	0.0022	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000142	0.00199	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000142	0.00199	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000138	0.00194	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000138	0.00193	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—BCHE—multiple sclerosis	0.000138	0.00193	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.000135	0.0019	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000129	0.00181	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	0.000129	0.00181	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000127	0.00178	CbGpPWpGaD
Methoxsalen—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000123	0.00173	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—SRM—multiple sclerosis	0.00012	0.00169	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000113	0.00159	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000113	0.00158	CbGpPWpGaD
Methoxsalen—CYP2A6—Biological oxidations—POMC—multiple sclerosis	0.000112	0.00157	CbGpPWpGaD
Methoxsalen—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	9.98e-05	0.0014	CbGpPWpGaD
Methoxsalen—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.5e-05	0.00133	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	9.05e-05	0.00127	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	9.05e-05	0.00127	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—SRM—multiple sclerosis	8.97e-05	0.00126	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	8.8e-05	0.00124	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	8.78e-05	0.00123	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	8.61e-05	0.00121	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—CYP27B1—multiple sclerosis	8.48e-05	0.00119	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—CYP24A1—multiple sclerosis	8.48e-05	0.00119	CbGpPWpGaD
Methoxsalen—CYP1A1—Biological oxidations—POMC—multiple sclerosis	8.31e-05	0.00117	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—APOE—multiple sclerosis	8.28e-05	0.00116	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	8.2e-05	0.00115	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	8.2e-05	0.00115	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—GPC5—multiple sclerosis	7.76e-05	0.00109	CbGpPWpGaD
Methoxsalen—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.7e-05	0.00108	CbGpPWpGaD
Methoxsalen—CYP2A6—NRF2 pathway—TGFB1—multiple sclerosis	7.33e-05	0.00103	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—POMC—multiple sclerosis	7.11e-05	0.000999	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—ALB—multiple sclerosis	6.48e-05	0.000911	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—RRM1—multiple sclerosis	6.43e-05	0.000903	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—CYP24A1—multiple sclerosis	6.32e-05	0.000888	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—CYP27B1—multiple sclerosis	6.32e-05	0.000888	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	6.18e-05	0.000868	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—GPC5—multiple sclerosis	5.78e-05	0.000812	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—SRM—multiple sclerosis	5.72e-05	0.000804	CbGpPWpGaD
Methoxsalen—CYP1A2—Biological oxidations—POMC—multiple sclerosis	5.3e-05	0.000745	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—RRM1—multiple sclerosis	4.79e-05	0.000673	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—SRM—multiple sclerosis	4.41e-05	0.00062	CbGpPWpGaD
Methoxsalen—CYP3A4—Biological oxidations—POMC—multiple sclerosis	4.09e-05	0.000575	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	4.03e-05	0.000566	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	4.03e-05	0.000566	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.94e-05	0.000553	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.71e-05	0.000522	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—BCHE—multiple sclerosis	3.69e-05	0.000519	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—GPC5—multiple sclerosis	3.68e-05	0.000518	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.19e-05	0.000449	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	3.11e-05	0.000437	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	3.11e-05	0.000437	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—RRM1—multiple sclerosis	3.05e-05	0.000429	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.91e-05	0.000409	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—GPC5—multiple sclerosis	2.84e-05	0.0004	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—BCHE—multiple sclerosis	2.75e-05	0.000387	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.37e-05	0.000333	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.36e-05	0.000331	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—APOE—multiple sclerosis	2.22e-05	0.000312	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.03e-05	0.000286	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—POMC—multiple sclerosis	1.91e-05	0.000268	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.86e-05	0.000261	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—BCHE—multiple sclerosis	1.75e-05	0.000246	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—ALB—multiple sclerosis	1.74e-05	0.000244	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—APOE—multiple sclerosis	1.65e-05	0.000233	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—POMC—multiple sclerosis	1.42e-05	0.0002	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.35e-05	0.00019	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—ALB—multiple sclerosis	1.3e-05	0.000182	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—APOE—multiple sclerosis	1.05e-05	0.000148	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—POMC—multiple sclerosis	9.06e-06	0.000127	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—ALB—multiple sclerosis	8.26e-06	0.000116	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—APOE—multiple sclerosis	8.14e-06	0.000114	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—POMC—multiple sclerosis	6.99e-06	9.83e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—ALB—multiple sclerosis	6.38e-06	8.96e-05	CbGpPWpGaD
